NCT02065154View on ClinicalTrials.gov

Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis

PHASE2CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

August 27, 2013

Primary Completion Date

April 30, 2022

Study Completion Date

April 30, 2022

Conditions
LeukemiaLymphomaMyelodysplastic SyndromeMyelofibrosisSevere Aplastic AnemiaAllogeneic Transplant
Interventions
DRUG

Cyclophosphamide

Trial Locations (1)

35249

UAB Bone Marrow Transplantation and Cellular Therapy Program, Birmingham

All Listed Sponsors
lead

University of Alabama at Birmingham

OTHER

NCT02065154 - Post Transplant Cyclophosphamide (Cytoxan) for GvHD Prophylaxis | Biotech Hunter | Biotech Hunter